title: [Changes of dendritic cells in prostate cancer and dendritic cell-based immunotherapy].
abstract: As the potent professional antigen present cell, dendritic cells (DC) play an important role in the initiation for anti-tumor immunity. Prostate cancer (PCa) can reduce the number and function of tumor infiltrated dendritic cells (TIDC) by a series of complicated mechanisms, escaping from immunosurveillance. With the development of immunology, more and more studies focus on TIDC and DC-based vaccines for PCa. However, all these studies are still at the exploratory stage. Here is a review of the related literature.
authors.affiliation: Research Laboratory of Prostate Diseases, Tianjin Urology Institute, Tianjin 300211, China. yongshiqi@163.com
authors.forename: Shi-yong
authors.initials: SY
authors.lastname: Qi
authors.forename: Meng
authors.initials: M
authors.lastname: Wang
authors.forename: Yong
authors.initials: Y
authors.lastname: Xu
mesh_terms: D019496:Cancer Vaccines / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines